Loading...
Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody Tafasitamab in relapsed/refractory DLBCL
Tafasitamab (MOR208) is an Fc-enhanced, humanized, monoclonal antibody that targets CD19. The L-MIND (NCT02399085) trial, an open-label, single-arm, phase II study of Tafasitamab (TAFA) plus lenalidomide (LEN), reported progression-free survival of 16 months in R/R DLBCL patients ineligible for auto...
Na minha lista:
| Udgivet i: | Leuk Res Rep |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Elsevier
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8322434/ https://ncbi.nlm.nih.gov/pubmed/34354920 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lrr.2021.100260 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|